Drug Profile
FF 21101 Y 90
Alternative Names: FF 21101-Y-90; FF-21101; FF-21101(90Y)Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator FUJIFILM Holdings Corporation
- Developer FUJIFILM Holdings Corporation; Strategia Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Biliary cancer; Head and neck cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Biliary-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (Parenteral)
- 28 May 2023 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (Parenteral)
- 28 May 2023 No recent reports of development identified for phase-I development in Ovarian-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (Parenteral)